From: Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab?
Assessment by irRC simulating RECIST1.0
Assessment by irRC simulating RECIST1.1
irCR
irPR
irSD
irPD
1
0
8
10
52
53
6
7
9
54
71